FMW Media’s New to The Street TV, a nationally syndicated TV show,
announces episode #356 airing tonight, Monday, June 20, 2022, at
10:30 PM PT on the Fox Business Network.
New to The Street’s 356th
TV episode airs tonight, featuring the following four (4) Companies
and their representatives:
1). Tonix Pharmaceuticals,
Inc.’s (NASDAQ: TNXP) interview with Dr. Seth Lederman, MD,
and CEO.
2). Sekur Private Data, Ltd.’s (OTCQX:
SWISF) (CSE: SKUR) (FRA: GDT0) interview with Mr. Alain Ghiai,
CEO.
3). PetVivo Holdings, Inc.’s (NASDAQ: PETV)
(NASDAQ: PETVW) interview with Mr. Mark Middleton, National Sales
Director.
4). Leflair's (Society Pass, Inc. subsidiary)
(NASDAQ: SOPA) interview with Mr. Loic Gautier, CEO.
Tonight, CEO, Dr. Seth Lederman, MD at Tonix
Pharmaceuticals, Inc. (NASDAQ: TNXP), is back in the studio at the
Nasdaq Marketplace speaking with New to The Street’s TV Host Jane
King. Recently, TNXP released data during three oral presentations
at the 2022 American Transplant Congress held at the Center of
Transplantation Sciences, Massachusetts General Hospital. TNX-1500
sees exciting results as a therapy in eliminating transplant
rejections in the heart and kidneys. Through a collaboration with
Massachusetts General Hospital, part of the Harvard Medical School,
the TNX-1500 shows data for possible product development for
therapeutic prevention of organ transplant rejection. TNX-1500
shows exciting results to date. A particular molecule, CD40-ligand
(CD40L) appears to be the reason for transplant rejections. TNXP
engineered a monotherapy to block toxicities associated with CD40L;
its TNX-1500 in animal studies shows activities to prevent
rejections. Dr. Lederman talks about the monkeypox virus and
compares the West African and Central African variants. The West
African is the one the press reports about, with infections
worldwide not appearing deadly. The Central African variant, with
no reported cases, can be lethal. TNXP has two patented vaccines,
one for smallpox and the other for monkeypox. TNX-801 is a
horsepox-based live virus vaccine currently in development to
protect against monkeypox and smallpox. The monkeypox vaccine is
in-testing with lab monkeys; so far, results look promising in
possible prevention. The Company’s fibromyalgia and Long-COVID
studies and clinical trials continue at TNXP. Exciting times for
the Company for their novel therapies and treatments; Dr. Lederman
will come back on a future show with further updates. The on-screen
QR code is available during the show; download or visit Tonix
Pharmaceuticals, Inc. - https://www.tonixpharma.com/.
New to The Street TV, tonight is re-airing the
in-studio interview at the Nasdaq Marketplace with Mr. Alain
Ghiai, CEO at Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR)
(FRA: GDT0). Alain talks with TV Host Jane King about the Company’s
newest encrypted product, “Chat-by-Invite.” This new text message
tool, available in the USA, Canada, Australia, New Zealand,
Switzerland, and most of Latin America and Europe, gives
subscribers an utterly private chat. It works when the Sekur
subscriber sends a text message to a recipient, and a link
appears that opens into a private, secure platform hosted in
Switzerland. Essentially, the chat occurs on the Swiss servers
owned and controlled by Sekur Private Data, Ltd. Once the text
message session completes, the text disappears. Hackers won’t know
about the transmission because of the highly encrypted military
technology operating the product. There is no direct texting on
open-source platforms, making them invulnerable to cybersecurity
breaches. The SekurMail / SekurMessenger, SekurVoice,
SekurProVideo Conference, and other products are available now or
soon. Sekur’s “Chat-by-Invite” app is available on iOS and Android;
go to Sekur.com to download it. Subscribers get
cybersecurity protections not available with open-source programs
for reasonable pricing. As an added protection to subscribers,
Sekur Private Data, Ltd operates its internet platforms and
security businesses under the country of Switzerland’s very tough
privacy laws. The on-screen QR code is available during the show;
download or visit Sekur Private Data, Ltd. – http://www.Sekur.com.
This interview segment initially aired on May 16, 2022.
Mr. Mark Middleton, National Sales Director at
PetVivo Holdings, Inc. (NASDAQ: PETV)
(NASDAQ: PETVW) and TV Host Jane King will talk on New to The
Street TV tonight about the Company and its products. PetVivo
Holdings, Inc. is a biomedical device company that manufactures,
commercializes, and licenses innovative medical devices and
therapeutics for companion animals. As PETV’s National Sales
Director, Mark talks about his history within the pet products
industry, dealing with FDA manufacturing, product distributions,
capital markets, and mergers/acquisitions. He sees himself as a
perfect fit at PETV; he understands the veterinarians (DVMs) needs
for best practices and product result outcomes for their clients’
animals. The injectable patented Spryng with OsteoCushion
Technology treats osteoarthritis and joint afflictions while
providing rehabilitation treatments for horses and dogs and
continues to grow as a reliable DVM treatment. Being an
entirely naturally derived product, Spryng is superior to
competitors’ non-biological, synthetic products, and the Spryng
treatment lasts longer. The PETV has a talent team who understands
science, finance, sales/marketing, manufacturing, distribution,
etc. With patience, persistence, and follow-through, Mark sees a
strong future for PETV. The on-screen QR code is available during
the show; download or visit PetVivo Holdings,
Inc. - https://petvivo.com/ and Spryng with
OsteoCushion Technology -
https://www.sprynghealth.com/.
On New to The Street TV tonight, Mr. Loic Gautier,
CEO at Leflair, a Society Pass, Inc. (NASDAQ: SOPA) subsidiary, has
his interview with TV Host Jane King. Loic provides viewers with
his history in e-commerce and online retail, how Leflair started
and eventually became a wholly-owned subsidiary of Society Pass,
Inc. Digital commerce takes money and commitment to succeed, Loic
explains the business model at Leflair, an e-commerce platform
specializing in fashion, and its growth within Vietnam and SE Asia.
During COVID-19 shutdowns, e-commerce sites that sold non-essential
goods/services had a tough time, Leflair was able to survive the
downtrend during 2020 and, in 2021, merged successfully into
Society Pass, Inc., a Nasdaq public Company. The relationship
between Leflair and Society is a win-win, giving Society Pass a
business vertical and Leflair access to capital and human resource
talents. Leflair fits perfectly in Society Pass, Inc.’s objective
to continue building the next generation of digital ecosystems and
loyalty programs in Southeast and South Asia markets. The on-screen
QR code is available during the show; download or visit Leflair -
https://leflair.com/en/ and Society Pass, Inc. -
https://thesocietypass.com/.
About Tonix Pharmaceuticals Holding Corp.
(NASDAQ: TNXP):
Tonix Pharmaceuticals Holding Corp. (NASDAQ:
TNXP) is a clinical-stage biopharmaceutical company focused on
discovering, licensing, acquiring, and developing small molecules
and biologics to treat and prevent human disease and alleviate
suffering. Tonix’s portfolio comprises immunology, rare disease,
infectious disease, and central nervous system (CNS) product
candidates. Tonix’s immunology portfolio includes biologics to
address organ transplant rejection, autoimmunity, and cancer.
TNX-15001 is a humanized monoclonal antibody targeting CD40-ligand
in development to prevent allograft and xenograft rejection and for
the treatment of autoimmune diseases. A Phase 1 study of TNX-1500
is expected to be initiated in the second half of 2022. Tonix’s
rare disease portfolio includes TNX-29002 for the treatment of
Prader-Willi syndrome. The FDA has granted TNX-2900 Orphan-Drug
Designation. Tonix’s infectious disease pipeline consists of a
vaccine in development to prevent smallpox and monkeypox called
TNX-8013, next-generation vaccines to prevent COVID-19, and an
antiviral to treat COVID-19. Tonix’s lead vaccine candidates for
COVID-19 are TNX-1840 and TNX-18504, live virus vaccines based on
Tonix’s recombinant pox vaccine (RPV) platform. TNX-35005
(sangivamycin, i.v. solution) is a small molecule
antiviral drug to treat acute COVID-19 and is in the pre-IND stage
of development. TNX-102 SL, (cyclobenzaprine HCl sublingual
tablets) is a small molecule drug being developed to treat Long
COVID, a chronic post-acute COVID-19 condition. Tonix expects to
initiate a Phase 2 study in Long COVID in the second quarter of
2022. The Company’s CNS portfolio includes small molecules and
biologics to treat pain, neurologic, psychiatric and addiction
conditions. Tonix’s lead CNS candidate, TNX-102 SL, is in mid-Phase
3 development to manage fibromyalgia, with a new Phase 3 study
launched in the second quarter of 2022. Finally, TNX-13006 is a
biologic designed to treat cocaine intoxication that is expected to
start a Phase 2 trial in the second quarter of 2022
- https://www.tonixpharma.com. (1TNX-1500 is an
investigational new biologic at the pre-IND stage of development
and has not been approved for any indication.2TNX-2900 is an
investigational new drug at the pre-IND stage of development and
has not been approved for any indication.3TNX-801 is a live
horsepox virus vaccine for percutaneous administration in
development to protect against smallpox and monkeypox. TNX-801 is
an investigational new biologic and has not been approved for any
indication.4TNX-1840 and TNX-1850 are live horsepox virus vaccines
for percutaneous administration, in development to protect against
COVID-19. TNX-1840 and TNX-1850 are designed to express the
SARS-CoV-2 spike protein from the omicron and BA.2 variants,
respectively. TNX-1840 and TNX-1850 are investigational new
biologics at the pre-IND stage of development and have not been
approved for any indication. 5TNX-3500 is an investigational new
drug at the pre-IND stage of development and has not been approved
for any indication.6TNX-1300 is an investigational new biologic and
has not been approved for any indication.)
About Sekur Private Data Ltd. (OTCQX:
SWISF) (CSE: SKUR) (FRA: GDT0):
Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE:
SKUR) (FRA: GDT0) is a Cybersecurity and
Internet privacy provider of Swiss-hosted solutions for secure
communications and secure data management. The Company distributes
encrypted emails, secure messengers, secure communication tools,
secure cloud-based storage, disaster recovery, and document
management products. The Company sells and serves consumers,
businesses, and governments worldwide through approved wholesalers,
distributors, and telecommunications companies. Contact Sekur
Private Data, Ltd. at corporate@globexdatagroup.com or
visit https://www.sekurprivatedata.com and https://www.sekur.com.
About PetVivo Holdings, Inc. (NASDAQ:
PETV) (NASDAQ: PETVW):
PetVivo Holdings, Inc. (NASDAQ: PETV)
(NASDAQ: PETVW) is an emerging biomedical device company currently
focused on manufacturing, commercializing, and licensing innovative
medical devices and therapeutics for companion animals. The
Company’s strategy is to leverage human therapies to treat
companion animals time-efficiently and less costly. A key component
of this strategy is the accelerated timeline to revenues for
veterinary medical devices that enter the market much earlier than
more stringently regulated pharmaceuticals and biologics. PetVivo
has a pipeline of seventeen products to treat animals and people. A
portfolio of nineteen patents protects the Company’s biomaterials,
products, production processes, and use methods. The Company’s lead
product Spryng with OsteoCushion Technology, a
veterinarian-administered, intraarticular injection to treat
lameness and other joint-related affliction, including
osteoarthritis, in dogs and horses, is currently available for
commercial sale to veterinarians
- https://petvivo.com/ & https://www.sprynghealth.com/.
About
Leflair, a Society Pass,
Inc. (NASDAQ: SOPA) Subsidiary:
Leflair, based in Ho Chi Minh City, Vietnam, is an
online premium outlet for Fashion, Beauty, and Home Furnishing
products. In December 2015, Leflair sold over 2,500 brands via its
flash-sales model. Society Pass, Inc. (NASDAQ: SOPA) acquired
Leflair’s assets in February 2021 and relaunched Leflair back onto
the Vietnam market in September 2021. SOPA
operates Leflair.com, Vietnam’s leading lifestyle e-commerce
platform. Society Pass, Inc. is building the next-generation
loyalty and data-focused marketing platform in Southeast Asia and
South Asia. The Company’s technology ecosystem enables companies to
work synergistically, transforming how consumers and merchants
interact. It is all about generating customer loyalty and revenue
for merchants and ease of consumer transactions. More transaction
data becomes available as more merchants and consumers register on
the platform. More data generation creates opportunities to develop
loyalty programs - https://thesocietypass.com/ &
https://leflair.com/en/.
About FMW Media:
FMW Media operates one of the longest-running US
and International sponsored and Syndicated Nielsen Rated
programming TV brands, “New to The Street” and its blockchain show
“Exploring The Block.” Since 2009, these brands have run
biographical interview segment shows across major U.S. Television
networks. The paid for TV programming platforms can potentially
reach over 540 million homes in the US and international markets.
FMW’s New to The Street / Newsmax TV broadcasting platform airs its
syndication on Sundays at 10 -11 AM ET. FMW is also one of the
nation’s largest buyers of linear television, long and short-form
paid programming
- https://www.newsmaxtv.com/Shows/New-to-the-Street & https://www.newtothestreet.com/.
Forward-Looking Statements
Disclaimer:
This press release contains forward-looking
statements within Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934. In
some cases, you can identify forward-looking statements by the
following words: “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,”
“potential,” “predict,” “project,” “should,” “will,” “would,” or
the negative of these terms or other comparable terminology.
However, not all forward-looking statements contain these words.
Forward-looking statements are not a guarantee of future
performance or results and will not necessarily be accurate
indications of the times at which such performance or results are
achieved. This press release should be considered in all filings of
the Companies contained in the Edgar Archives of the Securities and
Exchange Commission at www.sec.gov.
CONTACT:
FMW Media Contact:
Bryan Johnson +1 (631) 766-7462
Bryan@NewToTheStreet.com
“New to The Street” Business Development Office
1-516-696-5900 Support@NewtoTheStreet.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/c058bf8b-54d1-439a-b8ea-4cdd07074ee2
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Aug 2024 to Sep 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Sep 2023 to Sep 2024